Re: Overall Survival of Men with Metachronous Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy

被引：0

作者：

Sweeney, C. J.

Martin, A. J.

Stockler, M. R.

Begbie, S.

Chi, K. N.

Chowdhury, S.

Coskinas, X.

Frydenberg, M.

Hague, W. E.

Horvath, L. G.

Joshua, A. M.

Lawrence, N. J.

Marx, G. M.

McCaffrey, J.

McDermott, R.

McJannett, M.

North, S. A.

Parnis, F.

Parulekar, W.

Pook, D. W.

Reaume, M. N.

Sandhu, S. K.

Tan, A.

Tan, T. H.

Thomson, A.

Tu, E.

Vera-Badillo, F.

Williams, S. G.

Yip, S.

Zhang, A. Y.

Zielinski, R. R.

Davis, I. D.

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Harvard Med Sch, Boston, MA 02115 USA

[3] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia

[4] Concord Repatriat Gen Hosp, Concord Canc Ctr, Concord, Australia

[5] Chris Obrien Lifehouse RPA, Sydney, NSW, Australia

[6] Port Macquarie Base Hosp, Port Macquarie, NSW, Australia

[7] Mid North Coast Canc Inst Port Macquarie, Port Macquarie, NSW, Australia

[8] BC Canc Agcy, Vancouver, BC, Canada

[9] Univ British Columbia, Vancouver, BC, Canada

[10] CRUK & Kings Coll London, Guys & St Thomas NHS Fdn Trust Biomed Res Ctr, London, England

[11] Sarah Cannon Res UK, London, England

[12] Monash Univ, Melbourne, Vic, Australia

[13] Australian Urol Associates, Melbourne, Vic, Australia

[14] St Vincents Hosp, Kinghorn Canc Ctr, Sydney, NSW, Australia

[15] Garvan Inst Med Res, Sydney, NSW, Australia

[16] Auckland City Hosp, Auckland, New Zealand

[17] Sydney Adventist Hosp, Wahroonga, Australia

[18] Canc Trials Ireland, Dublin, Ireland

[19] Mater Misericordiae Univ Hosp, Dublin, Ireland

[20] St Vincents Univ Hosp, Dublin, Ireland

[21] Univ Coll Dublin, Dublin, Ireland

[22] ANZUP Canc Trials Grp, Camperdown, NSW, Australia

[23] Cross Canc Inst, Edmonton, AB, Canada

[24] Univ Alberta, Edmonton, AB, Canada

[25] Adelaide Canc Ctr, Adelaide, SA, Australia

[26] Univ Adelaide, Adelaide, SA, Australia

[27] Queens Univ, Canadian Canc Trials Grp CCTG, Kingston, ON, Canada

[28] Monash Hlth, Melbourne, Vic, Australia

[29] Univ Ottawa, Ottawa, ON, Canada

[30] Ottawa Hosp Res Inst, Ottawa, ON, Canada

[31] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[32] Univ Melbourne, Melbourne, Vic, Australia

[33] Waikato Dist Hlth Board, Hamilton, New Zealand

[34] Royal Adelaide Hosp, Adelaide, SA, Australia

[35] Royal Cornwall Hosp, Truro, Cornwall, England

[36] Kingston Hlth Sci Ctr, Kingston, ON, Canada

[37] Macquarie Univ, Sydney, NSW, Australia

[38] Orange Hlth Serv, Cent West Canc Care Ctr, Orange, Australia

[39] Univ Western Sydney, Sydney, NSW, Australia

[40] Eastern Hlth, Melbourne, Vic, Australia

来源：

JOURNAL OF UROLOGY | 2021年 / 206卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1519 / 1520

页数：3

共 50 条

[31] Are There Still Patients with Metastatic Hormone-sensitive Prostate Cancer Who Should Be Treated with Androgen Deprivation Monotherapy?
Kretschmer, Alexander
Todenhoefer, Tilman
EUROPEAN UROLOGY FOCUS, 2019, 5 (02): : 114 - 116
[32] Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Murphy, Declan G.
Zargar, Homayoun
EUROPEAN UROLOGY, 2016, 69 (03) : 540 - 540
[33] Re: Chemohormonal Therapy in Metastatic Hormone-sensitive Prostate Cancer
de Reijke, Theo
EUROPEAN UROLOGY, 2016, 69 (01) : 178 - 178
[34] Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis
Rydzewska, Larysa H. M.
Burdett, Sarah
Vale, Claire L.
Clarke, Noel W.
Fizazi, Karim
Kheoh, Thian
Mason, Malcolm D.
Miladinovic, Branko
James, Nicholas D.
Parmar, Mahesh K. B.
Spears, Melissa R.
Sweeney, Christopher J.
Sydes, Matthew R.
NamPhuong Tran
Tierney, Jayne F.
EUROPEAN JOURNAL OF CANCER, 2017, 84 : 88 - 101
[35] Addition of docetaxel or abiraterone to androgen deprivation therapy in metastatic hormone-sensitive prostate cancer in Indian population
Gupta, Alok
Hussain, Shaik Maheboob
Sonthwal, Neha
Chaturvedi, Harit
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2021, 17 (02) : 389 - 392
[36] Systemic Therapy for the Treatment of Hormone-Sensitive Metastatic Prostate Cancer: from Intermittent Androgen Deprivation Therapy to Chemotherapy
Liaw, Bobby C.
Shevach, Jeffrey
Oh, William K.
CURRENT UROLOGY REPORTS, 2015, 16 (03)
[37] Systemic Therapy for the Treatment of Hormone-Sensitive Metastatic Prostate Cancer: from Intermittent Androgen Deprivation Therapy to Chemotherapy
Bobby C. Liaw
Jeffrey Shevach
William K. Oh
Current Urology Reports, 2015, 16
[38] Prognostic model for second progression-free survival and overall survival in patients with high-risk metastatic hormone-sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy
Narita, Shintaro
Yanagisawa, Takafumi
Hatakeyama, Shingo
Hata, Kenichi
Fujita, Kazutoshi
Ueda, Takashi
Tanaka, Toshikazu
Maita, Shinya
Chiba, Shuji
Sato, Hiromi
Sekine, Yuya
Kobayashi, Mizuki
Kashima, Soki
Yamamoto, Ryohei
Numakura, Kazuyuki
Saito, Mitsuru
Takayama, Koichiro
Okane, Katsumi
Ishida, Toshiya
Horikawa, Yohei
Kumazawa, Teruaki
Shimoda, Jiro
Iwabuchi, Ikuya
Suzuki, Takehiro
Ukimura, Osamu
Kimura, Takahiro
Ohyama, Chikara
Nomura, Kyoko
Habuchi, Tomonori
PROSTATE, 2025, 85 (01): : 73 - 81
[39] The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES
Armstrong, Andrew J.
Iguchi, Taro
Azad, Arun A.
Villers, Arnauld
Alekseev, Boris
Petrylak, Daniel P.
Szmulewitz, Russell Z.
Alcaraz, Antonio
Shore, Neal D.
Holzbeierlein, Jeffrey
Gomez-Veiga, Francisco
Rosbrook, Brad
Zohren, Fabian
Haas, Gabriel P.
Gourgiotti, Georgia
El-Chaar, Nader
Stenzl, Arnulf
EUROPEAN UROLOGY, 2023, 84 (02) : 229 - 241
[40] Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer
Wenzel, Mike
Hoeh, Benedikt
Chun, Felix K. H.
Mandel, Philipp
UROLOGIE, 2023, 62 (04): : 360 - 368

← 1 2 3 4 5 →